The Effects of Nitazoxanide in Hepatic Encephalopathy

• Status: Unknown status
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluating the efficacy and safety of nitazoxanide in comparison to standard treatment in patients with grade II-III hepatic encephalopathy (HE). Also, Evaluating the effect of administering nitazoxanide on the improvement of patient's quality of life.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Collaborator: Al-Azhar University
• Treatments: Lactulose; Metronidazole; Nitazoxanide

Criteria

Inclusion Criteria:

• Adult Patients from 18 to 65 years.

• Patients with grade II-III Hepatic Encephalopathy.

Exclusion Criteria:

• Patients with active GIT bleeding.

• Patients with major psychiatric illness.

• Patients receiving benzodiazepines, narcotics, alcohol and marijuana.

• Patients with compromised renal or biliary functions.

• Patients known to have AIDS.

• Patients receiving medications highly bound to plasma proteins eg. Warfarin.

• Patients with known hypersensitivity to nitazoxanide.

• Pregnant or lactating women.